2-butoxy-9-(1-tert-butoxycarbonylpiperidin-4-ylmethyl)-8-methoxyadenine | 930777-62-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-butoxy-9-(1-tert-butoxycarbonylpiperidin-4-ylmethyl)-8-methoxyadenine
• 英文别名: 1,1-dimethylethyl 4-{[6-amino-2-(butyloxy)-8-(methyloxy)-9H-purin-9-yl]methyl}-1-piperidinecarboxylate；1,1-dimethylethyl 4-[6-amino-2-butoxy-8-methoxypurin-9-yl]methyl-1-piperidinecarboxylate；tert-butyl 4-[(6-amino-2-butoxy-8-methoxypurin-9-yl)methyl]piperidine-1-carboxylate
• CAS: 930777-62-1
• 化学式: C₂₁H₃₄N₆O₄
• 分子量: 434.539
• InChiKey: LHXFTQGZRNHWFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  118
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-butoxy-9-(1-tert-butoxycarbonylpiperidin-4-ylmethyl)-8-methoxyadenine 在 盐酸 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 6-amino-2-butoxy-9-(N-(2-hydroxyethyl)-4-piperidinylmethyl)-8-hydroxypurine hydrochloride
  参考文献：
  名称：

  [EN] LIPIDATED OXOADENINE DERIVATIVES
  [FR] DÉRIVÉS D'OXOADÉNINE LIPIDÉS

  摘要：

  包含氮杂环取代氧代腺嘌呤分子的新型脂质化氧代腺嘌呤，通过共价键连接到磷脂或膦脂的化合物被证明是干扰素-a和其他免疫刺激细胞因子的诱导剂。这些化合物可用作免疫刺激剂和辅助剂。

  公开号：

  WO2011017611A1
• 作为产物：
  描述：

  8-bromo-2-butoxy-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 在 potassium carbonate 、 三氟乙酸 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 73.0h， 生成 2-butoxy-9-(1-tert-butoxycarbonylpiperidin-4-ylmethyl)-8-methoxyadenine
  参考文献：
  名称：

  Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity

  摘要：

  Toll-like receptors 7 and 8 (TLR7/8) agonists are potent immunostimulants that are attracting considerable interest as vaccine adjuvants. We recently reported the synthesis of a new series of 2-O-butyl-8-oxoadenines substituted at the 9-position with various linkers and N-heterocycles, and showed that TLR7/8 selectivity, potency and cytokine induction could be modulated by varying the alkyl linker length and the N-heterocyclic ring. In the present study, we further optimized the oxoadenine scaffold by investigating the effect of different substituents at the 2-position of the oxoadenine on TLR7/8 potency/selectivity, cytokine induction and DC maturation in human PBMCs. The results show that introducing a 1-(S)-methylbutoxy group at the 2-position of the oxoadenine significantly increased potency for TLR7/8 activity, cytokine induction and DC maturation.

  DOI：

  10.1016/j.bmcl.2020.126984

文献信息

• [EN] NOVEL ADENINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'ADÉNINE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2010018134A1

  公开（公告）日：2010-02-18

  Compounds of formula (I) wherein R1 is C1-6alkylamino, or C1-6alkoxy; R2 is a group having the structure (II): n is an integer having a value of 1 to 6; Het is a 6-membered saturated heterocycle containing one nitrogen atom wherein Het is attached to the -(CH2)n- moiety at any carbon atom of the heterocycle; R3 is hydrogen, C1-8alkyl, or C3-7cycloalkylC0-6alkyl; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.

  式(I)的化合物中，其中R1是C1-6烷基氨基或C1-6烷氧基；R2是具有结构(II)的基团：n是一个值为1至6的整数；Het是一个含有一个氮原子的6元饱和杂环，其中Het连接到杂环的任何碳原子上的-(CH2)n-基团；R3是氢、C1-8烷基或C3-7环烷基C0-6烷基；以及其盐是人干扰素的诱导剂。诱导人干扰素的化合物可能在治疗各种疾病中有用，例如治疗过敏性疾病和其他炎症性疾病，例如过敏性鼻炎和哮喘，治疗传染性疾病和癌症，并且还可能作为疫苗佐剂有用。
• Novel Adenine Compound
  申请人：Hashimoto Kazuki

  公开号：US20080269240A1

  公开（公告）日：2008-10-30

  An adenine compound useful as a medicine represented by the following formula (1): [wherein R 1 is halogen atom, optionally substituted alkyl group, optionally substituted aryl group, etc.; X is oxygen atom, sulfur atom, a single bond, etc.; A 1 is optionally substituted and optionally saturated 4 to 8 membered heterocyclic group containing 1 to 2 hetero atoms selected from 1 to 3 nitrogen atoms, 0 to 1 oxygen atom, and 0 to 1 sulfur atom; A 2 is optionally substituted 6 to 10 cyclic aromatic hydrocarbon group or optionally substituted 5 to 10 membered heterocyclic aromatic group; L 1 and L 2 are independently, substituted straight or branched alkylene or a single bond, etc.; L 3 is optionally substituted straight or branched alkylene, etc.; R 2 is hydrogen atom, optionally substituted alkyl group.] or its pharmaceutically acceptable salt.

  以下式子（1）所表示的一种腺嘌呤化合物，可用作药物：[其中，R1是卤素原子、可选取代烷基、可选取代芳基等；X是氧原子、硫原子、单键等；A1是可选取代和可饱和的4至8元杂环基，包含1至2个从1至3个氮原子、0至1个氧原子和0至1个硫原子中选取的杂原子；A2是可选取代的6至10环芳烃基或可选取代的5至10元杂环芳烃基；L1和L2是独立的、取代的直链或支链烷基或单键等；L3是可选取代的直链或支链烷基等；R2是氢原子、可选取代烷基等。]或其药学上可接受的盐。
• NOVEL ADENINE DERIVATIVES
  申请人：Bazin-Lee Helene

  公开号：US20110144136A1

  公开（公告）日：2011-06-16

  The present invention relates to compounds of formula (I): wherein R 1 is C 1-6 alkylamino, or C 1-6 alkoxy; R 2 is a group having the structure: n is an integer having a value of 1 to 6; Het is a 6-membered saturated heterocycle containing one nitrogen atom wherein Het is attached to the —(CH 2 ) n — moiety at any carbon atom of the heterocycle; R 3 is hydrogen, C 1-8 alkyl, or C 3-7 cycloalkylC 0-6 alkyl; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.

  本发明涉及式(I)的化合物：其中R1是C1-6烷基氨基或C1-6烷氧基；R2是具有结构的基团：n是具有值为1到6的整数；Het是含有一个氮原子的6元饱和杂环，其中Het连接到杂环的任何碳原子上的—(CH2)n—基团；R3是氢、C1-8烷基或C3-7环烷基C0-6烷基；以及它们的盐是人干扰素的诱导剂。诱导人干扰素的化合物可能在治疗各种疾病方面有用，例如治疗过敏性疾病和其他炎症性疾病，例如过敏性鼻炎和哮喘，治疗传染病和癌症，也可能作为疫苗佐剂有用。
• Adenine derivatives
  申请人：Bazin-Lee Helene

  公开号：US08563717B2

  公开（公告）日：2013-10-22

  The present invention relates to compounds of formula (I): wherein R1 is C1-6alkylamino, or C1-6alkoxy; R2 is a group having the structure: n is an integer having a value of 1 to 6; Het is a 6-membered saturated heterocycle containing one nitrogen atom wherein Het is attached to the —(CH2)n— moiety at any carbon atom of the heterocycle; R3 is hydrogen, C1-8alkyl, or C3-7cycloalkylC0-6alkyl; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.

  本发明涉及公式（I）的化合物：其中R1为C1-6烷基氨基或C1-6烷氧基；R2是具有结构的基团：n为1至6的整数；Het是含有一个氮原子的6元饱和杂环，其中Het连接到杂环的任何碳原子处于—（CH2）n—基团上；R3为氢、C1-8烷基或C3-7环烷基C0-6烷基；以及其盐是人类干扰素的诱导剂。诱导人类干扰素的化合物可以用于治疗各种疾病，例如过敏性疾病和其他炎症性疾病，例如过敏性鼻炎和哮喘，感染性疾病和癌症的治疗，也可以作为疫苗佐剂有用。
• NOVEL ADENINE COMPOUND
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1939199A1

  公开（公告）日：2008-07-02

  An adenine compound useful as a medicine represented by the following formula (1): [wherein R1 is halogen atom, optionally substituted alkyl group, optionally substituted aryl group, etc.; X is oxygen atom, sulfur atom, a single bond, etc.; A1 is optionally substituted and optionally saturated 4 to 8 membered heterocyclic group containing 1 to 2 hetero atoms selected from 1 to 3 nitrogen atoms, 0 to 1 oxygen atom, and 0 to 1 sulfur atom; A2 is optionally substituted 6 to 10 cyclic aromatic hydrocarbon group or optionally substituted 5 to 10 membered heterocyclic aromatic group; L1 and L2 are independently, substituted straight or branched alkylene or a single bond, etc.; L3 is optionally substituted straight or branched alkylene, etc.; R2 is hydrogen atom, optionally substituted alkyl group.] or its pharmaceutically acceptable salt.

  由下式(1)表示的一种可用作药物的腺嘌呤化合物： [其中 R1 是卤素原子、任选取代的烷基、任选取代的芳基等； X 是氧原子、硫原子、单键等； A1 是任选取代的和任选饱和的 4 至 8 个成员的 A1 是任选取代且任选饱和的 4 至 8 个成员的杂环基团，含有 1 至 2 个选自 1 至 3 个氮原子、0 至 1 个氧原子和 0 至 1 个硫原子的杂原子； A2 是任选取代的 6 至 10 个环芳烃基团或任选取代的 5 至 10 个杂环芳烃基团； L1 和 L2 独立地是取代的直链或支链亚烷基或单键等； L3 是任选取代的直链或支链亚烷基等； R2 是氢原子、任选取代的烷基]。 或其药学上可接受的盐。